# Causal links between mitophagy and Alzheimer's disease: a Mendelian randomization study

Weijian Zhang <sup>1,2</sup>¶, Wenjia Chen<sup>2&</sup>, Zhendong Guo<sup>1&</sup>, Hui Li<sup>2,3</sup>¶\*

1 The Second Clinical College, Guangzhou University of Chinese Medicine, Guangzhou, P.R.

China

2 Research Group of Standardization for Chinese medicine, Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese

Medicine), Guangzhou, P.R. China

3 State Key Laboratory of Dampness Syndrome of Chinese Medicine, Guangzhou, P.R. China

\* Corresponding author. Address: Guangdong Provincial Hospital of Chinese Medicine (The Second Affiliated Hospital of Guangzhou University of Chinese Medicine), No. 111 Dade Rd, Yuexiu District, Guangzhou, Guangdong Province, China. Tel: +86-20-81887233. E-mail: lihuitcm@126.com (H. Li).

# Background

Emerging evidence highlights the dysregulation of mitophagy, the process of clearing damaged mitochondria, as a potential contributor to Alzheimer's disease (AD) pathology. However, the precise mechanisms linking mitophagy to AD remain poorly understood. This study utilized summary-data-based Mendelian Randomization (SMR) combined with multiomics data to explore the causal relationships between them, and to uncover potential epigenetic mechanisms of gene regulation.

## Methods

Mitophagy-related genes were identified through the integration of three databases, and transcriptomic data of AD patients were obtained from the Gene Expression Omnibus (GEO) database. A meta-analysis was conducted to recognize differentially expressed genes (DEGs) associated with mitophagy in AD. Through SMR tools, genome-wide association study (GWAS) summary data of AD from the GWAS Catalog (n=487,511) were separately integrated with expression quantitative trait loci (eQTLs) and DNA methylation quantitative trait loci (mQTLs) from blood and brain tissues to identify potentially causal genes and methylation sites. The findings from primary analysis were validated with data from the UK Biobank (n=301,478).

## Results

In total, 111 mitophagy-related genes were found to be differentially expressed in AD. The three-step SMR analysis identified two genes, PARL and BCL2L1, from blood tissues and three genes, ATG13, TOMM22, and SPATA33, from brain tissues as causal candidate genes associated with AD. The analysis pinpointed the possible epigenetic mechanisms, where specific methylation sites regulate the expression of these genes, potentially contributing to

their association with AD. All findings were successfully replicated in UK Biobank cohorts.

# Conclusions

The study emphasized the putatively causal relationships of mitophagy-related gene with AD.

These underlying pathogenic mechanisms could pave the way for new approaches in early

detection and therapeutic intervention for AD.

Keywords Mitophagy, Alzheimer's disease, multi-omics, Mendelian randomization

# 1 Background

2 Alzheimer's disease (AD), the leading cause of dementia in older adults worldwide, is a 3 progressive, age-related neurodegenerative disorder characterized by memory impairment, 4 cognitive decline, personality changes, and language disorders [1]. Its major pathological 5 features include amyloid beta (AB) plaques, neurofibrillary tangles of hyperphosphorylated 6 tau (p-tau), and neuroinflammation. Although the etiology of AD remains poorly understood, 7 it is generally believed that the multifaceted interplay of genetic variation, environmental 8 factors, and lifestyle underpins the pathogenesis of AD, especially in sporadic cases [2]. 9 The brain is one of the most energy-demanding organs, and brain cells are particularly 10 vulnerable to mitochondrial damage [3]. The homeostasis of both neurons and glial cells is 11 heavily dependent on the normal function of mitophagy, the central component of 12 mitochondrial quality control [4]. Mitophagy refers to the selective degradation of defective 13 mitochondria via the autophagy pathway [5]. By removing dysfunctional mitochondria in 14 neurons and supporting glial cells, mitophagy not only reduces cellular damage caused by 15 reactive oxygen species (ROS) and mitochondrial DNA (mtDNA) leakage, but also enhances 16 microglial phagocytosis of misfolded proteins like AB and tau in neurodegenerative diseases 17 [6]. This process helps to attenuate neuroinflammation, primarily induced by the release of 18 pro-inflammatory cytokines or ROS, and maintain cellular homeostasis in AD models, thereby 19 preventing bioenergetic failure and cell death [7].

20 Mounting evidence implicates that mitophagy is significantly dysregulated in the brains of AD 21 patients and AD models, which may be one of the underlying contributors to the 22 manifestation and pathophysiology of the disease [8]. Altered expression levels of several

4

23 mitophagy-related proteins, such as PINK1, p62, and LC3, have been observed in post24 mortem human AD brains [9, 10].

25 Impaired mitophagy exacerbates oxidative damage and cellular energy depletion, leading to 26 the aggregation of AB and p-tau proteins, which in turn disrupt the mitophagy mechanism 27 itself [11]. PINK1/Parkin signaling, involving proteins such as PINK1, Parkin, and p62, is an 28 important pathway regulating mitophagy [12]. PINK1-deficient mAPP mice exhibited earlier 29 and increased A $\beta$  accumulation, mitochondrial dysfunction, and cognitive impairment [13], 30 while knocking out the p62 gene accelerated p-tau aggregation and neurodegeneration in 31 PS19 mice [14]. Experimental evidence showed that upregulation of mitophagy-related 32 proteins by genetic or pharmacological intervention could potentially increase mitophagy flux 33 and ameliorate cognitive deficits in AD models [11, 13, 15]. 34 Epigenetic modifications, particularly aberrant DNA methylation (DNAm) at CpG sites 35 introduced by environmental factors, also play a vital role in AD development [16]. Both global 36 and site-specific DNA hypomethylation have been found in post-mortem AD human brains 37 and AD animal models [17, 18]. DNA methylation status in specific gene promoter or enhancer 38 regions can affect  $A\beta$  deposition and neurofibrillary tangle formation by altering gene 39 expression [19]. For example, hypomethylation in the promoter of BACE1 or PSEN1, both 40 integral to the A $\beta$  production, increases A $\beta$  aggregates in AD mice by upregulating the

41 expression of these genes [20, 21].

Multiple genome-wide association studies (GWAS) in AD patients have successfully identified
several genetic susceptibility loci related to mitochondrial function, including APOE, TOMM40,
and CLU, especially in late-onset AD cases [22-24]. Furthermore, methylome-wide association

5

45 studies (MWAS) have also detected numerous AD-related DNA methylation marks, notably

46 in genes such as APOE, MAPT, ANK1, and HOXA3 [25-27].

47 Despite these findings, which have expanded our knowledge of the genetic architecture and 48 epigenetic mechanisms in AD, the associations identified from GWAS and MWAS may not be 49 the direct genetic causes of the disease due to confounding effects from environmental and 50 genetic factors [28, 29]. The specific role of mitophagy-related genes and their regulatory 51 elements in AD remains elusive.

52 Summary data-based Mendelian randomization (SMR) is a method that combines GWAS data 53 with molecular trait data, such as expression quantitative trait loci (eQTL) and DNA 54 methylation QTL (mQTL), with the objective of investigating putative causal relationships 55 between the molecular signatures and diseases [30]. Given that AD is a progressive 56 neurodegenerative disorder affecting the central nervous system [31], analyzing the putative 57 effects of genetic variants on brain-expressed genes may yield more meaningful insights than 58 blood-based analyses. Accordingly, we employed a three-step SMR approach, integrating AD 59 GWAS summary statistics with eQTL/mQTL data from blood and brain tissues separately, to 60 investigate gene expressions and DNAm sites potentially causally linked to AD.

Furthermore, the replication analysis using data from UK Biobank datasets validated findingsfrom the primary analysis to ensure the robustness and reliability of the discovery.

## 63 Methods

## 64 Study design

65 The study design is illustrated in Figure 1. Initially, a meta-analysis of transcriptomic data was66 conducted to recognize differentially expressed genes (DEGs) associated with mitophagy in

67 AD patients. Subsequently, the three-step SMR approach integrated AD GWAS summary 68 statistics with eQTL/mQTL data of DEGs to identify potential causal relationships between 69 these genes and AD. The SMR tests were conducted using eQTL and mQTL data from blood 70 tissues, separately. Genes and methylation sites identified as significant in the primary analysis 71 were then validated using data from UK Biobank. 72 Fig 1. Flowchart of the study. AD, Alzheimer's disease; cis-eQTLs, cis-expression quantitative 73 trait loci; cis-mQTL, cis-methylation quantitative trait loci; GWAS, Genome-wide association 74 studies; SMR, summary-based Mendelian randomization; SNP, single nucleotide 75 polymorphisms.

#### 76 Data resources

Mitophagy-related genes were retrieved from the Gene Set Enrichment Analysis (GSEA),
Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology Resource (GO) using
the search terms "mitophagy". Five microarray datasets for AD patients were gained from the
Gene Expression Omnibus (GEO) database (<u>http://www.ncbi.nlm.nih.gov/geo/</u>) (S1 Table) [32-

**81** 44].

82 In the primary analysis, GWAS summary statistics for AD from the GWAS Catalog were used, 83 consisting of a total of 487,511 individuals, including 39,106 clinically diagnosed AD cases, 84 46,828 proxy cases, and 401,577 controls [45]. These data were obtained from a meta-analysis 85 of AD GWAS datasets collected across 15 European countries, combining results from the 86 European Alzheimer & Dementia Biobank (EADB) consortium and the UK Biobank. The data 87 GWAS GCST90027158 can be accessed publicly via the Catalog -88 (https://www.ebi.ac.uk/gwas/studies/GCST90027158).

89 For external validation, we utilized GWAS summary data from the UK Biobank, encompassing 90 a total of 301,478 individuals, with 25,392 AD cases and 276,086 controls [45]. The proxy-AD 91 cases were determined based on questionnaire data in which individuals were asked if their 92 parents had a diagnosis of dementia. All individuals analyzed in both the primary analysis and 93 validation stages were of European ancestry. 94 Blood eQTL summary data of mitophagy-related genes were procured from eQTLGen, which 95 contains statistics on blood gene expression from 31,684 individuals [46]. Blood mQTL data obtained through a meta-analysis implemented on two cohorts (n=1,980) [47]. Brain eQTL 96 97 data were derived from BrainMeta v2 cis-eQTL summary data project (n= 2,865) [48], while 98 the brain mQTL data were derived from the Brain-mMeta mQTL dataset (n = 1,160), generated 99 through a meta-analysis that combined data from the studies by ROSMAP et al., Hannon et 100 al., and Jaffe et al. [49]. This study focused on cis-eQTLs and cis-mQTLs, defined as single 101 nucleotide polymorphisms (SNPs) located within a 1000 kb range upstream or downstream 102 of the gene of interest.

103 For comprehensive details about the data used in the study, please refer to Supporting104 information.

- 105 Statistical analysis
- 106 Identification of DEGs

107 DEGs related to mitophagy between AD patients and healthy controls (HCs) were identified 108 using linear regression models for each dataset, with adjustments for age, sex, and other 109 relevant covariates to account for potential confounding factors. A meta-analysis with a fixed-110 effects model was then carried out using the R package *metafor* to integrate the DEGs from

111 individual datasets and derive the final set of DEGs [50].

### 112 SMR for detecting putative causal relationship

- 113 SMR tools were specifically designed to assess whether genetic variants influence complex
- 114 traits through intermediate molecular traits, such as gene expression, DNA methylation, or
- 115 protein abundance [30]. The 1000 Genomes European reference was used to calculate linkage
- 116 disequilibrium [51], while the heterogeneity of dependent instruments (HEIDI) tests were
- employed for the assessment of heterogeneity [30].
- 118 The SMR analysis was conducted three times respectively using molecular QTL data from
- 119 blood and brain tissues, with SNPs serving as genetic instrument variables in all three steps:
- 120 (1) blood or brain eQTLs as exposures, with AD as the outcome; (2) blood or brain mQTLs as
- 121 exposures, with AD as the outcome; (3) significant findings from step 1 as exposures, and
- 122 findings from step 2 as outcomes. The significant causal associations were identified in
- 123 accordance with the following criteria: (1) passing all three-step SMR with the threshold of
- 124  $P_{SMR-multi} < 0.05$ ; (2) demonstrating genome-wide significance, with  $P < 1 \times 10^{-5}$  across all QTL
- datasets; and (3) displaying no significant heterogeneity ( $P_{HEIDI} > 0.05$ ).

## 126 **Results**

#### 127 DEGs associated with mitophagy

128 After removing duplicates, 167 unique mitophagy-related genes were collected from three

- databases (S2 Table). The recognition of DEGs was conducted on each of the five microarray
- 130 datasets to contrast the expression levels of transcripts between AD patients (n=401) and HCs
- 131 (n=388) (S1 Table). After the meta-analysis of results from these five datasets, 111 mitophagy-
- related genes were recognized as DEGs in AD (P < 0.05) (Fig 2 and S3 Table).

#### 133 Fig 2. Volcano Plot of differentially expressed genes (DEGs) related to mitophagy in AD. A

- 134 meta-analysis of five microarray datasets was conducted to compare gene expression
- 135 between AD patients and healthy controls. In volcano plot, the x-axis represents meta-analysis
- 136 effect sizes, while the y-axis shows the -log of meta *p* value, indicating statistical significance.
- 137 Red dots highlight the 111 significant differentially expressed genes (DEGs), while black dots
- **138** represent non-significant genes. The dashed line marks the significance threshold at p < 0.05.

#### 139 Integration of GWAS and mitophagy-related eQTL/mQTL data from

140 blood and brain tissues

As outlined previously, we sought to identify candidate causal genes for AD and elucidate the
 epigenetic mechanisms involved. Our three-step SMR analysis combined AD GWAS summary
 statistics from the GWAS Catalog with blood or brain cis-eQTLs/cis-mQTLs data of 111

144 mitophagy-related DEGs.

145 Integrating blood eQTL data from the eQTLGen Consortium (n = 31,684) with AD GWAS

summary data identified 5 mitophagy-related genes (*P<sub>SMR-multi</sub>* < 0.05, *P<sub>HEIDI</sub>* > 0.05) (S4 Table).

147 Similarly, the integration of blood mQTL data (n = 1,980) with the same AD GWAS data

148 identified 676 CpG sites (*P<sub>SMR-multi</sub>* < 0.05, *P<sub>HEIDI</sub>* > 0.05) (S5 Table). Further analysis combining

149 the putative causal signals from the first two steps resulted in the identification of 6 CpG sites

- **150** associated with the expression of two genes: PARL and BCL2L1 ( $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ )
- 151 (S6 Table).

152 In a similar manner, leveraging eQTL (n = 2,865) and mQTL (n = 1,160) data from brain tissues 153 along with the same AD GWAS summary statistics, we identified 9 mitophagy-related genes 154 and 83 CpG sites ( $P_{SMR-multi} < 0.05$ ,  $P_{HFIDI} > 0.05$ ) (S7 and S8 Table). By combining findings from

155	transcriptome and methylome data, the third analysis filtered out 7 CpG sites that putatively
156	regulate the expression of three genes: ATG13, TOMM22, and SPATA33 ( $P_{SMR-multi}$ < 0.05, $P_{HEIDI}$
157	>0.05) (S9 Table).
158	The integration of multi-omics data from blood and brain tissues provides evidence
159	supporting the causal relationships between mitophagy-related gene expression and AD
160	pathogenesis, as shown in <b>Table 1</b> .

#### 161 Table 1. Associations of mitophagy-related gene expression with AD identified through three-

Analysis Type	Cono		Π	Π	nsnp	botaSMP	
	Analysis Type	Gene	TOP SINP <sup>a</sup>	∽SMR-multi	Pheidi	HEIDI	Delasivin
-	Blood-based	PARL	rs7644746	4.69 × 10 <sup>-3</sup>	0.18	20	-0.13
	analysis	BCL2L1	rs6088962	$5.04 \times 10^{-3}$	0.11	20	0.41
	Brain tissue	ATG13	rs756343	1.94 × 10 <sup>-2</sup>	0.15	20	0.03
		TOMM22	rs926299	2.89 × 10 <sup>-2</sup>	0.61	20	0.05
	analysis	SPATA33	rs258334	1.81 × 10 <sup>-3</sup>	0.10	20	-0.05

#### 162 step SMR analysis

163 AD, Alzheimer's disease; SMR, summary-based Mendelian randomization; SNP, single

value from HEIDI test (Heterogeneity in Dependent Instruments); nsnp HEIDI: The number of

166 SNPs used in the HEIDI test; beta<sub>SMR</sub>, effect size from SMR analysis.

<sup>a</sup> Top SNP refers to the most significantly associated SNP with gene expression within a cis-

168 eQTL region and it is used to estimate the effect of gene expression on trait.

<sup>169</sup> Plausible epigenetic regulation of mitophagy-related genes by DNA

170 methylation in AD

<sup>164</sup> nucleotide polymorphism;  $P_{SMR-multi}$ , p value from multi-SNP-based SMR method;  $P_{HEIDI}$ , p

171 The three-step SMR analysis gave us an opportunity to speculate on the genetic regulation 172 model of mitophagy-related genes in AD. One illustrative case is the PARL gene, which 173 encodes a serine rhomboid protease located in the mitochondrial intermembrane space and 174 is involved in regulating mitophagy by mediating the cleavage of PINK1 and PGAM5 [52, 53]. DNAm site cg22921096 in the 5' untranslated region, 453 kbp downstream of PARL, was 175 176 identified in the integration analysis of mQTL and AD GWAS summary statistics. The methylation level of this site exerted a positive effect on PARL expression (beta<sub>SMR</sub> = 0.07) and 177 178 a negative effect on AD (beta<sub>SMR</sub> = -0.03). In addition, the PARL expression level was inversely 179 related to the disease onset (beta<sub>SMR</sub> = -0.13). Collectively, these results suggest that higher 180 methylation level at this site upregulates the transcript level of PARL, potentially offering a 181 protective effect against AD risk (Fig 3A). 182 ATG13, a key component of the ULK1 complex, is integral to the initiation of autophagy and 183 mitophagy. Our analysis revealed a positive causal correlation between the ATG13 expression and DNAm site cq05585544, 957 kbp downstream of ATG13 (beta<sub>SMR</sub> = 0.13). The elevated 184 185 expression of ATG13 gene (beta<sub>SMR</sub> = 0.03) and methylation levels of this CpG site (beta<sub>SMR</sub> = 186 0.05) potentially increased the susceptibility to AD. Therefore, it is hypothesized that the 187 genetic variation modulates the DNAm status at this CpG site, leading to upregulation of 188 ATG13 expression, which could contribute to a heightened risk of AD (Fig 3B). 189 Fig 3. Three-step SMR analyses using molecular traits from blood and brain tissues. SMR tools

190

- along with relevant epigenetic mechanisms of genetic regulation (all  $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} >$
- 192 0.05). The panels, from left to right, depict the following analysis results: SMR between gene

were used to prioritize the mitophagy-related genes potentially causally associated with AD,

193	expression and AD GWAS on the left, SMR between gene methylation and AD GWAS in the
194	middle, and SMR between gene methylation and gene expression. Panels A and B present
195	the respective results for the genes PARL and ATG13. eQTL, expression quantitative trait loci;
196	GWAS, Genome-wide association studies; mQTL, DNA methylation quantitative trait loci
197	External replication of mitophagy-related DEGs in AD GWAS summary
198	statistics from UK Biobank
198 199	statistics from UK Biobank For external replication, we made use of AD GWAS data from the UK Biobank (n=361,141) and
198 199 200	<b>statistics from UK Biobank</b> For external replication, we made use of AD GWAS data from the UK Biobank (n=361,141) and integrated them with eQTLs and mQTLs of previously detected genes to validate our primary
198 199 200 201	statistics from UK Biobank For external replication, we made use of AD GWAS data from the UK Biobank (n=361,141) and integrated them with eQTLs and mQTLs of previously detected genes to validate our primary findings. All tested genes and relevant DNAm sites showed significant associations with AD

203 Table).

## 204 Discussion

205 This is the first study to identify mitophagy-related genes and their corresponding 206 methylation sites potentially causally linked to AD. Dysregulation of mitophagy results in the 207 buildup of defective mitochondria, which contribute to progression of AD pathologies such 208 as AB aggregation, tau protein abnormalities, and neuroinflammation [5]. Targeting 209 mitophagy has emerged as a promising therapeutic strategy, with animal model studies 210 demonstrating its effectiveness in counteracting these pathological features and clinically 211 improving cognitive deficits [54]. Since mitophagy-related DEGs in AD may either be a cause 212 or an outcome of neurodegenerative processes [5, 55], it is essential to clarify the roles of 213 these genes in AD development and their interactions with other biomolecules from a genetic 214 perspective. By incorporating multi-omics data from different tissues through the SMR

215 method, we identified a potentially causal relationship between five mitophagy-related genes 216 and AD, and investigated their genetic regulatory mechanisms via epigenomic modifications. 217 Among the genes filtered out by the three-step SMR, most of them have been characterized 218 in AD field. For instance, PARL, a susceptibility locus for AD, regulates mitophagy through the 219 PINK1-Parkin pathway [56]. A recent genome-wide survival study and gene analysis have 220 reported that the downregulation of PARL expression correlated with worsening clinical 221 symptoms of AD [57]. Lower PARL expression has been shown to increase p-tau levels in 222 different AD models, while overexpression of PARL reduced this accumulation in basic 223 experiment [57]. Our study further identified the CpG methylation in the 5' untranslated region increased transcript level of PARL, potentially promoting its protective effect against 224 225 AD (beta<sub>SMR</sub> = -0.13).

Elevated levels of Bcl-xL have been observed in the brain tissues of AD patients [58]. The
BCL2L1 gene encodes the Bcl-xL protein, an anti-apoptotic member of the Bcl-2 family, which
modulates both apoptotic pathways and autophagy process, including mitophagy.
Specifically, Bcl-xL inhibits mitophagy by binding to the BH3-like domain of Beclin 1, a key
protein in the initiation and regulation of the process [59]. The inhibitory interaction between
Beclin 1 and Bcl-xL could suppress activity of Beclin 1, thereby impairing mitophagy and
exacerbating AD pathology [60].

ATG13, a vital component of the autophagy machinery, also plays an essential role in mitophagy processes [61]. At the onset of mitophagy, ATG13 forms the ULK complex with ULK1/2, ATG101 and FIP200, and the ULK complex initiates mitophagy by facilitating the formation and maturation of mitophagosomes [62], a structure that engulfs damaged

237 mitochondria and delivers them to lysosomes for degradation.

238	Another significant finding from the three-step SMR analysis in brain tissue is the identification
239	of TOMM22, a critical receptor within the translocase of the outer mitochondrial membrane
240	(TOMM) complex, responsible for importing Parkin into mitochondria under normal
241	conditions [63]. Previous studies have demonstrated that the destabilization of TOMM22 and
242	TOMM40 acts as the switch to trigger the mitophagy [64]. Moreover, overexpression of
243	TOMM22 partially inhibits Parkin-mediated mitochondrial clearance, suggesting that the
244	proper regulation of TOMM22 is important for maintaining mitochondrial quality control [64].
245	Interestingly, SPATA33, identified as an autophagy mediator by recent experimental study,
246	promotes the mitophagy in the male germline cells during spermatogenesis by interacting
247	with the outer mitochondrial membrane protein VDAC2 and the autophagy-related protein
248	ATG16L1 [65, 66]. The brain tissue analysis has suggested SPATA33 as a novel candidate gene
249	potentially linked to AD development, although research in this area remains limited.
250	The strength of our investigation lies in the integration of multi-omics data from multiple
251	tissues, providing a comprehensive analysis of the causal associations between mitophagy-
252	related genes and AD. The three-step SMR with a more stringent statistical filtering criteria
253	provided us stronger evidence to support our inference and enhanced our understanding of
254	the genetic regulation mechanism involved in AD. Finally, all prioritized genes from the
255	primary analysis were replicated in the other datasets, which further supported the reliability
256	of the findings.

257 This study has some limitations that are worth acknowledging. First, eQTLs change in response258 to different cell states and environmental conditions [67]. Second, this study focused

15

- 259 exclusively on cis-eQTLs and cis-mQTLs. Third, the participants included in these datasets
- 260 were individuals of European ancestry, and the lack of ancestral diversity limits the applicability
- 261 of our findings to more ethnically diverse populations.

## 262 Conclusions

- 263 In conclusion, our study emphasized the potential causal links between mitophagy-related
- 264 genes and AD. We identified biological mechanisms where DNA methylation modifications
- 265 modulates the expression of specific mitophagy-related genes, thereby influencing the onset
- and progression of AD. These insights offer a deeper understanding of the pathogenesis of
- AD and hold significant implications for the development of novel therapeutic targets.

## 268 Supporting information

- 269 S1 Table. Characteristics of 5 microarray datasets.
- 270 S2 Table. 167 mitophagy-related genes list.
- 271 S3 Table. Meta-analysis of 111 differentially expressed genes related to mitophagy from five

272 datasets (p < 0.05). Estimate, combined effect size estimate; SE, standard error of the effect

- size estimate; Cl.lb, lower bound of the 95% confidence interval; Cl.ub, upper bound of the
- 274 95% confidence interval.

275 S4 Table. Summary-based Mendelian randomization (SMR) analysis from blood gene 276 expression to AD (all  $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ). ID, identifier; Chr, chromosome; bp, base

277 pair position; SNP, single nucleotide polymorphisms; A1, effect (coded) allele; A2, other allele;

- 278 Freq, frequency of effect allele; b, effect size; GWAS, Genome-Wide Association Studies; se,
- 279 standard error; p, p-value; eQTL, expression quantitative trait locus; SMR, summary-based
- 280 Mendelian randomization; SMR-multi, multi-SNP-based SMR; HEIDI, Heterogeneity in

- 281 Dependent Instruments test; nsnp HEIDI, number of SNPs used in the HEIDI test.
- 282 S5 Table. SMR analysis from blood DNA methylation to AD (all *P<sub>SMR-multi</sub>* < 0.05, *P<sub>HEIDI</sub>* > 0.05).
- 283 SMR, summary-based Mendelian randomization.
- 284 S6 Table. SMR analysis from blood DNA methylation to gene expression (all P<sub>SMR-multi</sub> < 0.05,
- 285 *P<sub>HEIDI</sub>* > 0.05). Expo, exposure; ID, identifier; Chr, chromosome; bp: base pair position; Outco;
- 286 outcome; A1: effect allele; A2: other allele; Freq: frequency of the effect allele (A1); b: effect
- size; se: standard error; p, p value; SMR, summary-based Mendelian randomization; SMR-
- 288 multi, multi-SNP-based SMR; HEIDI, Heterogeneity in Dependent Instruments test; nsnp HEIDI,
- 289 number of SNPs used in the HEIDI test.
- 290 S7 Table. SMR analysis from brain gene expression to AD (all *P<sub>SMR-multi</sub>* < 0.05, *P<sub>HEIDI</sub>* > 0.05).
- S8 Table. SMR analysis from brain DNA methylation to AD (all  $P_{SMR-multi} < 0.05$ ,  $P_{HEIDI} > 0.05$ ).
- 292 S9 Table. SMR analysis from brain DNA methylation to gene expression (all P<sub>SMR-multi</sub> < 0.05,
- 293  $P_{HEIDI} > 0.05$ ).
- 294 S10 Table. External validation of the UK Biobank database

# 295 Acknowledgments

296 We thank all participants and investigators of the GWAS Catalog and UK Biobank.

# 297 Author Contributions

- 298 Conceptualization: Weijian Zhang, Wenjia Chen, Hui Li.
- 299 Data curation: Weijian Zhang, Zhendong Guo.
- **300** Formal analysis: Weijian Zhang, Wenjia Chen.
- 301 Methodology: Weijian Zhang, Zhendong Guo.
- **302** Software: Weijian Zhang, Zhendong Guo.

- 303 Validation: Zhendong Guo.
- 304 Visualization: Weijian Zhang.
- 305 Writing original draft: Weijian Zhang, Wenjia Chen, Zhendong Guo.
- **306** Writing review & editing: Weijian Zhang.
- **307** Funding acquisition: Hui Li.

#### 308 Reference

Tahami Monfared AA, Byrnes MJ, White LA, Zhang Q. Alzheimer's Disease: Epidemiology and
 Clinical Progression. Neurol Ther. 2022;11(2):553-69. Epub 20220314. doi: 10.1007/s40120-022-00338 8. PubMed PMID: 35286590; PubMed Central PMCID: PMC9095793.

Dunn AR, O'Connell KMS, Kaczorowski CC. Gene-by-environment interactions in Alzheimer's
 disease and Parkinson's disease. Neurosci Biobehav Rev. 2019;103:73-80. Epub 20190614. doi:
 10.1016/j.neubiorev.2019.06.018. PubMed PMID: 31207254; PubMed Central PMCID: PMC6700747.

Clemente-Suárez VJ, Redondo-Flórez L, Beltrán-Velasco AI, Ramos-Campo DJ, Belinchón-deMiguel
 P, Martinez-Guardado I, et al. Mitochondria and Brain Disease: A Comprehensive Review of Pathological
 Mechanisms and Therapeutic Opportunities. Biomedicines. 2023;11(9). Epub 20230907. doi:
 10.3390/biomedicines11092488. PubMed PMID: 37760929; PubMed Central PMCID: PMC10526226.

Yang X, Zhang Y, Luo J-x, Zhu T, Ran Z, Mu B-R, et al. Targeting mitophagy for neurological disorders
 treatment: advances in drugs and non-drug approaches. Naunyn-Schmiedeberg's Archives of
 Pharmacology. 2023;396(12):3503-28. doi: 10.1007/s00210-023-02636-w.

Mary A, Eysert F, Checler F, Chami M. Mitophagy in Alzheimer's disease: Molecular defects and
 therapeutic approaches. Mol Psychiatry. 2023;28(1):202-16. doi: 10.1038/s41380-022-01631-6.

Magalhães JD, Fão L, Vilaça R, Cardoso SM, Rego AC. Macroautophagy and Mitophagy in
Neurodegenerative Disorders: Focus on Therapeutic Interventions. Biomedicines. 2021;9(11). Epub
20211105. doi: 10.3390/biomedicines9111625. PubMed PMID: 34829854; PubMed Central PMCID:
PMC8615936.

Sukhorukov V, Voronkov D, Baranich T, Mudzhiri N, Magnaeva A, Illarioshkin S. Impaired
 Mitophagy in Neurons and Glial Cells during Aging and Age-Related Disorders. Int J Mol Sci. 2021;22(19).
 Epub 20210923. doi: 10.3390/ijms221910251. PubMed PMID: 34638589; PubMed Central PMCID:
 PMC8508639.

Sharma B, Pal D, Sharma U, Kumar A. Mitophagy: An Emergence of New Player in Alzheimer's
 Disease. Front Mol Neurosci. 2022;15:921908. Epub 20220706. doi: 10.3389/fnmol.2022.921908.
 PubMed PMID: 35875669; PubMed Central PMCID: PMC9296849.

Martín-Maestro P, Gargini R, García E, Perry G, Avila J, García-Escudero V. Slower Dynamics and
 Aged Mitochondria in Sporadic Alzheimer's Disease. Oxid Med Cell Longev. 2017;2017;9302761. Epub
 20171019. doi: 10.1155/2017/9302761. PubMed PMID: 29201274; PubMed Central PMCID:
 PMC5672147.

339 10. Vaillant-Beuchot L, Mary A, Pardossi-Piquard R, Bourgeois A, Lauritzen I, Eysert F, et al.
 340 Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure,

341 function, and mitophagy defects in Alzheimer's disease models and human brains. Acta Neuropathol.

342 2021;141(1):39-65. Epub 20201020. doi: 10.1007/s00401-020-02234-7. PubMed PMID: 33079262;
 343 PubMed Central PMCID: PMC7785558.

11. Fang EF, Hou Y, Palikaras K, Adriaanse BA, Kerr JS, Yang B, et al. Mitophagy inhibits amyloid-β and

tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci.
2019;22(3):401-12. Epub 20190211. doi: 10.1038/s41593-018-0332-9. PubMed PMID: 30742114;
PubMed Central PMCID: PMC6693625.

348 12. Zhou T-Y, Ma R-X, Li J, Zou B, Yang H, Ma R-Y, et al. Review of PINK1-Parkin-mediated
349 mitochondrial autophagy in Alzheimer's disease. Eur J Pharmacol. 2023;959:176057. doi:
350 https://doi.org/10.1016/j.ejphar.2023.176057.

351 13. Du F, Yu Q, Yan S, Hu G, Lue LF, Walker DG, et al. PINK1 signalling rescues amyloid pathology and
352 mitochondrial dysfunction in Alzheimer's disease. Brain. 2017;140(12):3233-51. doi:
353 10.1093/brain/awx258. PubMed PMID: 29077793; PubMed Central PMCID: PMC5841141.

14. Ono M, Komatsu M, Ji B, Takado Y, Shimojo M, Minamihisamatsu T, et al. Central role for
p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy. Aging Cell.
2022;21(7):e13615. Epub 20220605. doi: 10.1111/acel.13615. PubMed PMID: 35662390; PubMed
Central PMCID: PMC9282839.

Wang XJ, Qi L, Cheng YF, Ji XF, Chi TY, Liu P, et al. PINK1 overexpression prevents forskolin-induced
tau hyperphosphorylation and oxidative stress in a rat model of Alzheimer's disease. Acta Pharmacol
Sin. 2022;43(8):1916-27. Epub 20211210. doi: 10.1038/s41401-021-00810-5. PubMed PMID: 34893682;
PubMed Central PMCID: PMC9343460.

Maity S, Farrell K, Navabpour S, Narayanan SN, Jarome TJ. Epigenetic Mechanisms in Memory and
Cognitive Decline Associated with Aging and Alzheimer's Disease. Int J Mol Sci. 2021;22(22). Epub
20211113. doi: 10.3390/ijms222212280. PubMed PMID: 34830163; PubMed Central PMCID:
PMC8618067.

17. Cadena-del-Castillo C, Valdes-Quezada C, Carmona-Aldana F, Arias C, Bermúdez-Rattoni F,
Recillas-Targa F. Age-dependent increment of hydroxymethylation in the brain cortex in the tripletransgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2014;41(3):845-54. doi: 10.3233/jad132285. PubMed PMID: 24685633.

18. Shu L, Sun W, Li L, Xu Z, Lin L, Xie P, et al. Genome-wide alteration of 5-hydroxymenthylcytosine
in a mouse model of Alzheimer's disease. BMC Genomics. 2016;17:381. Epub 20160520. doi:
10.1186/s12864-016-2731-1. PubMed PMID: 27207465; PubMed Central PMCID: PMC4875608.

373 19. De Plano LM, Saitta A, Oddo S, Caccamo A. Epigenetic Changes in Alzheimer's Disease: DNA
374 Methylation and Histone Modification. Cells. 2024;13(8). Epub 20240421. doi: 10.3390/cells13080719.
375 PubMed PMID: 38667333; PubMed Central PMCID: PMC11049073.

20. Monti N, Cavallaro RA, Stoccoro A, Nicolia V, Scarpa S, Kovacs GG, et al. CpG and non-CpG
Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated
with gene expression in human and murine brain. Epigenetics. 2020;15(8):781-99. Epub 20200205. doi:
10.1080/15592294.2020.1722917. PubMed PMID: 32019393; PubMed Central PMCID: PMC7518704.

21. Do Carmo S, Hanzel CE, Jacobs ML, Machnes Z, Iulita MF, Yang J, et al. Rescue of Early bace-1 and
Global DNA Demethylation by S-Adenosylmethionine Reduces Amyloid Pathology and Improves
Cognition in an Alzheimer's Model. Sci Rep. 2016;6:34051. Epub 20160929. doi: 10.1038/srep34051.
PubMed PMID: 27681803; PubMed Central PMCID: PMC5041108.

384 22. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A genome-wide 385 association study with 1.126.563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet. 386 2021;53(9):1276-82. Epub 20210907. doi: 10.1038/s41588-021-00921-z. PubMed PMID: 34493870; 387 PubMed Central PMCID: PMC10243600.

388 23. Brabec JL, Lara MK, Tyler AL, Mahoney JM. System-level analysis of Alzheimer's disease prioritizes 389 candidate genes for neurodegeneration. Frontiers in Genetics. 2021;12:625246.

390 24. Sen A, Kalvakuri S, Bodmer R, Cox RT. Clueless, a protein required for mitochondrial function, 391 interacts with the PINK1-Parkin complex in Drosophila. Dis Model Mech. 2015;8(6):577-89. Epub 392 20150420. doi: 10.1242/dmm.019208. PubMed PMID: 26035866; PubMed Central PMCID: 393 PMC4457034.

394 25. Migliore L, Coppede F. Gene-environment interactions in Alzheimer disease: the emerging role of 395 epigenetics. Nat Rev Neurol. 2022;18(11):643-60. Epub 20220930. doi: 10.1038/s41582-022-00714-w. 396 PubMed PMID: 36180553.

397 26. Iwata A, Nagata K, Hatsuta H, Takuma H, Bundo M, Iwamoto K, et al. Altered CpG methylation in 398 sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. Hum Mol Genet. 399 2014;23(3):648-56. Epub 20130918. doi: 10.1093/hmg/ddt451. PubMed PMID: 24101602.

400 27. Li QS, Sun Y, Wang T. Epigenome-wide association study of Alzheimer's disease replicates 22 401 differentially methylated positions and 30 differentially methylated regions. Clin Epigenetics. 402 2020;12(1):149. Epub 20201017. doi: 10.1186/s13148-020-00944-z. PubMed PMID: 33069246; 403 PubMed Central PMCID: PMC7568396.

404 28. Lin X, Barton S, Holbrook JD. How to make DNA methylome wide association studies more 405 powerful. Epigenomics. 2016;8(8):1117-29. Epub 20160407. doi: 10.2217/epi-2016-0017. PubMed 406 PMID: 27052998; PubMed Central PMCID: PMC5066141.

407 29. Young AS. Genome-wide association studies have problems due to confounding: Are family-based 408 designs the answer? PLoS Biol. 2024;22(4):e3002568. Epub 20240412. doi: 409 10.1371/journal.pbio.3002568. PubMed PMID: 38607978; PubMed Central PMCID: PMC11014432.

410 30. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from 411 GWAS and eQTL studies predicts complex trait gene targets. Nat Genet. 2016;48(5):481-7. Epub 412 20160328. doi: 10.1038/ng.3538. PubMed PMID: 27019110.

413 31. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol 414 Neurodegener. 2019;14(1):32. doi: 10.1186/s13024-019-0333-5.

415 32. Hokama M, Oka S, Leon J, Ninomiya T, Honda H, Sasaki K, et al. Altered expression of diabetes-416 related genes in Alzheimer's disease brains: the Hisayama study. Cereb Cortex. 2014;24(9):2476-88. 417 Epub 20130417. doi: 10.1093/cercor/bht101. PubMed PMID: 23595620; PubMed Central PMCID: 418 PMC4128707.

419 33. Berchtold NC, Cribbs DH, Coleman PD, Rogers J, Head E, Kim R, et al. Gene expression changes in 420 the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A. 2008;105(40):15605-

421 10. Epub 20081001. doi: 10.1073/pnas.0806883105. PubMed PMID: 18832152; PubMed Central PMCID: 422 PMC2563070.

423 34. Berchtold NC, Coleman PD, Cribbs DH, Rogers J, Gillen DL, Cotman CW. Synaptic genes are 424 extensively downregulated across multiple brain regions in normal human aging and Alzheimer's 425 disease. Neurobiol 2013;34(6):1653-61. 20121227. doi: Aging. Epub 426 10.1016/j.neurobiolaging.2012.11.024. PubMed PMID: 23273601; PubMed Central PMCID: 427 PMC4022280.

428 35. Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ, et al. Extensive innate 429 immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and 430 neurodegeneration: a microarray study. J Neuroinflammation. 2012;9:179. Epub 20120723. doi: 431 10.1186/1742-2094-9-179. PubMed PMID: 22824372; PubMed Central PMCID: PMC3419089.

432 36. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, et al. Deficient liver biosynthesis 433 of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One. 434 2010;5(9):e12538. Epub 20100908. doi: 10.1371/journal.pone.0012538. PubMed PMID: 20838618; 435 PubMed Central PMCID: PMC2935886.

436 37. Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC, 3rd, Fontaine SN, et al. Accelerated 437 neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest. 438 2013;123(10):4158-69. Epub 20130903. doi: 10.1172/jci69003. PubMed PMID: 23999428; PubMed 439 Central PMCID: PMC3784538.

440 38. Sárvári M, Hrabovszky E, Kalló I, Solymosi N, Likó I, Berchtold N, et al. Menopause leads to elevated 441 expression of macrophage-associated genes in the aging frontal cortex: rat and human studies identify 442 strikingly similar changes. J Neuroinflammation. 2012;9:264. Epub 20121203. doi: 10.1186/1742-2094-443 9-264. PubMed PMID: 23206327; PubMed Central PMCID: PMC3558453.

444 39. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Walker DG, et al. Gene expression profiles 445 in anatomically and functionally distinct regions of the normal aged human brain. Physiol Genomics. 446 2007;28(3):311-22. Epub 20061031. doi: 10.1152/physiolgenomics.00208.2006. PubMed PMID: 447 17077275; PubMed Central PMCID: PMC2259385.

448 40. Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, et al. Alzheimer's disease is 449 associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc 450 Natl Acad Sci U S A. 2008;105(11):4441-6. Epub 20080310. doi: 10.1073/pnas.0709259105. PubMed 451 PMID: 18332434; PubMed Central PMCID: PMC2393743.

452 41. Readhead B, Haure-Mirande JV, Funk CC, Richards MA, Shannon P, Haroutunian V, et al. Multiscale 453 Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical 454 Networks by Human Herpesvirus. Neuron. 2018;99(1):64-82.e7. Epub 20180621. doi: 455 10.1016/j.neuron.2018.05.023. PubMed PMID: 29937276; PubMed Central PMCID: PMC6551233.

456 42. Liang WS, Dunckley T, Beach TG, Grover A, Mastroeni D, Ramsey K, et al. Altered neuronal gene 457 expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol 458 Genomics. 2008;33(2):240-56. Epub 20080212. doi: 10.1152/physiolgenomics.00242.2007. PubMed 459 PMID: 18270320; PubMed Central PMCID: PMC2826117.

460 43. McKay EC, Beck JS, Khoo SK, Dykema KJ, Cottingham SL, Winn ME, et al. Peri-Infarct Upregulation 461 of the Oxytocin Receptor in Vascular Dementia. J Neuropathol Exp Neurol. 2019;78(5):436-52. doi: 462 10.1093/jnen/nlz023. PubMed PMID: 30990880; PubMed Central PMCID: PMC6467199.

463 44. Piras IS, Krate J, Delvaux E, Nolz J, Mastroeni DF, Persico AM, et al. Transcriptome Changes in the 464 Alzheimer's Disease Middle Temporal Gyrus: Importance of RNA Metabolism and Mitochondria-465 Associated Membrane Genes. J Alzheimers Dis. 2019;70(3):691-713. doi: 10.3233/jad-181113. PubMed 466 PMID: 31256118.

467 45. Bellenguez C, Küçükali F, Jansen IE, Kleineidam L, Moreno-Grau S, Amin N, et al. New insights into 468 the genetic etiology of Alzheimer's disease and related dementias. Nat Genet. 2022;54(4):412-36. Epub 469 20220404. doi: 10.1038/s41588-022-01024-z. PubMed PMID: 35379992; PubMed Central PMCID: 470 PMC9005347.

471 46. Võsa U, Claringbould A, Westra HJ, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans-

472 eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene 473 expression. Nat Genet. 2021;53(9):1300-10. Epub 20210902. doi: 10.1038/s41588-021-00913-z. 474 PubMed PMID: 34475573; PubMed Central PMCID: PMC8432599.

475 47. Wu Y, Zeng J, Zhang F, Zhu Z, Qi T, Zheng Z, et al. Integrative analysis of omics summary data 476 reveals putative mechanisms underlying complex traits. Nat Commun. 2018;9(1):918. Epub 20180302.

477 doi: 10.1038/s41467-018-03371-0. PubMed PMID: 29500431; PubMed Central PMCID: PMC5834629.

478 48. Qi T, Wu Y, Fang H, Zhang F, Liu S, Zeng J, et al. Genetic control of RNA splicing and its distinct role

479 in complex trait variation. Nat Genet. 2022;54(9):1355-63. doi: 10.1038/s41588-022-01154-4.

480 49. Qi T, Wu Y, Zeng J, Zhang F, Xue A, Jiang L, et al. Identifying gene targets for brain-related traits 481 using transcriptomic and methylomic data from blood. Nature Communications. 2018;9(1):2282. doi: 482 10.1038/s41467-018-04558-1.

483 50. Viechtbauer W. Conducting Meta-Analyses in R with The metafor Package. Journal of Statistical 484 Software. 2010;36. doi: 10.18637/jss.v036.i03.

485 51. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A global reference for 486 human genetic variation. Nature. 2015;526(7571):68-74. doi: 10.1038/nature15393. PubMed PMID: 487 26432245; PubMed Central PMCID: PMC4750478.

488 52. Sekine S, Kanamaru Y, Koike M, Nishihara A, Okada M, Kinoshita H, et al. Rhomboid protease PARL 489 mediates the mitochondrial membrane potential loss-induced cleavage of PGAM5. J Biol Chem. 490 2012;287(41):34635-45. Epub 20120822. doi: 10.1074/jbc.M112.357509. PubMed PMID: 22915595; 491 PubMed Central PMCID: PMC3464569.

492 53. Lysyk L, Brassard R, Touret N, Lemieux MJ. PARL Protease: A Glimpse at Intramembrane 493 Proteolysis in the Inner Mitochondrial Membrane. J Mol Biol. 2020;432(18):5052-62. Epub 20200419. 494 doi: 10.1016/j.jmb.2020.04.006. PubMed PMID: 32320686.

495 54. Yang X, Zhang Y, Luo JX, Zhu T, Ran Z, Mu BR, et al. Targeting mitophagy for neurological disorders 496 treatment: advances in drugs and non-drug approaches. Naunyn Schmiedebergs Arch Pharmacol. 497 2023;396(12):3503-28. Epub 20230803. doi: 10.1007/s00210-023-02636-w. PubMed PMID: 37535076.

498 55. Jiménez-Loygorri JI, Boya P. Aging STINGs: mitophagy at the crossroads of neuroinflammation. 499 Autophagy. 2024;20(7):1684-6. Epub 20240306. doi: 10.1080/15548627.2024.2322421. PubMed PMID: 500 38411192; PubMed Central PMCID: PMC11210893.

501 56. Shi G, McQuibban GA. The Mitochondrial Rhomboid Protease PARL Is Regulated by PDK2 to 502 Integrate Mitochondrial Quality Control and Metabolism. Cell Rep. 2017;18(6):1458-72. doi: 503 10.1016/j.celrep.2017.01.029. PubMed PMID: 28178523.

504 57. Chen SD, Zhang W, Feng YW, Wu BS, Yang L, Zhang YR, et al. Genome-wide Survival Study Identifies 505 PARL as a Novel Locus for Clinical Progression and Neurodegeneration in Alzheimer's Disease. Biol 506 Psychiatry. 2023;94(9):732-42. Epub 20230303. doi: 10.1016/j.biopsych.2023.02.992. PubMed PMID: 507 36870520.

508 58. Kitamura Y, Shimohama S, Kamoshima W, Ota T, Matsuoka Y, Nomura Y, et al. Alteration of 509 proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain 510 Res. 1998;780(2):260-9. doi: 10.1016/s0006-8993(97)01202-x. PubMed PMID: 9507158.

511 59. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell 512 Death Differ. 2011;18(4):571-80. Epub 20110211. doi: 10.1038/cdd.2010.191. PubMed PMID: 513 21311563; PubMed Central PMCID: PMC3131912.

514 60. Salminen A, Kaarniranta K, Kauppinen A, Ojala J, Haapasalo A, Soininen H, et al. Impaired 515 autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome. Prog

516 Neurobiol. 2013;106-107:33-54. Epub 20130701. doi: 10.1016/j.pneurobio.2013.06.002. PubMed
517 PMID: 23827971.

518 61. Joo JH, Dorsey FC, Joshi A, Hennessy-Walters KM, Rose KL, McCastlain K, et al. Hsp90-Cdc37
519 chaperone complex regulates Ulk1- and Atg13-mediated mitophagy. Mol Cell. 2011;43(4):572-85. doi:
520 10.1016/j.molcel.2011.06.018. PubMed PMID: 21855797; PubMed Central PMCID: PMC3485687.

521 62. Fujita K, Kedashiro S, Yagi T, Hisamoto N, Matsumoto K, Hanafusa H. The ULK complex-LRRK1 axis
522 regulates Parkin-mediated mitophagy via Rab7 Ser-72 phosphorylation. J Cell Sci. 2022;135(23). Epub
523 20221207. doi: 10.1242/jcs.260395. PubMed PMID: 36408770; PubMed Central PMCID: PMC9789397.

63. Pitt AS, Buchanan SK. A Biochemical and Structural Understanding of TOM Complex Interactions
and Implications for Human Health and Disease. Cells. 2021;10(5). Epub 20210511. doi:
10.3390/cells10051164. PubMed PMID: 34064787; PubMed Central PMCID: PMC8150904.

64. Bertolin G, Ferrando-Miguel R, Jacoupy M, Traver S, Grenier K, Greene AW, et al. The TOMM
machinery is a molecular switch in PINK1 and PARK2/PARKIN-dependent mitochondrial clearance.
Autophagy. 2013;9(11):1801-17. Epub 20130905. doi: 10.4161/auto.25884. PubMed PMID: 24149440.
65. Xu X, Zhang Y, Cheng H, Zhou R. SPATA33 functions as a mitophagy receptor in mammalian
germline. Autophagy. 2021;17(5):1284-6. Epub 20210405. doi: 10.1080/15548627.2021.1909836.
PubMed PMID: 33818286; PubMed Central PMCID: PMC8143240.

533 66. Zhang Y, Xu X, Hu M, Wang X, Cheng H, Zhou R. SPATA33 is an autophagy mediator for cargo
534 selectivity in germline mitophagy. Cell Death Differ. 2021;28(3):1076-90. Epub 20201021. doi:
535 10.1038/s41418-020-00638-2. PubMed PMID: 33087875; PubMed Central PMCID: PMC7937689.

536 67. van der Wijst MGP, Brugge H, de Vries DH, Deelen P, Swertz MA, Franke L. Single-cell RNA
537 sequencing identifies celltype-specific cis-eQTLs and co-expression QTLs. Nat Genet. 2018;50(4):493-7.
538 Epub 20180402. doi: 10.1038/s41588-018-0089-9. PubMed PMID: 29610479; PubMed Central PMCID:
539 PMC5905669.

540

541



Fig 2. Volcano plot of differentially expressed genes related to m



Fig 3A. SMR between DNA methylation and AD (in the middle)



Fig 3A. SMR between PARL gene expression and AD (on the left)





Fig 3A. SMR between DNA methylation and PARL gene expressio



Fig 3B. SMR between ATG13 and AD (on the left)



Fig 3B. SMR between DNA methylation and AD (in the middle)



Fig 3B. SMR between DNA methylation and ATG13 (on the right)



Fig 1. Flowchart of the study.